Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient

Bibliography

• NEWMAN AB, SISCOVICK DS, MANOLIO TA et al.: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation (1993) 88:837–845.
   Google Scholar
• HIATT WR, HOAG S, HAMMAN RF: Effect of diagnostic criteria on the prevalence of peripheral arterial disease. Circulation (1995) 91:1472–1479.
   PubMed Web of Science ®Google Scholar
• ZHENG Z-J, SHARRETT AR, CHAMBLESS LE et al.: Association of ankle-brachial index with clinical coronary heart disease, stroke, and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis (1997) 131:115–125.
   PubMedGoogle Scholar
• FOWKES FGR, HOUSLEY E, CAWOOD EH, MACINTYRE CC, RUCKLEY CV, PRESCOTT RJ: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. (1991) 20:384–392.
   PubMedGoogle Scholar
• REUNANEN A, TAKKUNEN H, AROMAA A: Prevalence of intermittent claudication and its effect on mortality. Acta Med. Scand. (1982) 211:249–256.
   PubMedGoogle Scholar
• NEWMAN AB, SISCOVICK DS, MANOLIO TA et al:Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation (1993) 88:837–845.
   PubMed Web of Science ®Google Scholar
• ARONOW WS, AHN C: Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women or = 62 years of age. Am. J. Cardiol. (1994) 74:64–65.
   PubMed Web of Science ®Google Scholar
• •Seminal work on atherosclerotic overlap in various vascular beds.
   Google Scholar
• LENG GC, LEE AJ, FOWKES FG et al: Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. Int. J. Epidemiol. (1996) 25:1172–1181.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• MCKENNA M, WOLFSON S, KULLER LH: The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis (1991) 87:119–128.
   PubMed Web of Science ®Google Scholar
• VOGT MT, CAULEY JA, NEWMAN AB, KULLER LH, HULLEY SB: Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA (1993) 270:465–479.
   PubMed Web of Science ®Google Scholar
• HIATT WR: Preventing atherothromboticevents in peripheral arterial disease: the use of antiplatelet therapy. J. hit. Med. (2002) 251:193–206.
   Google Scholar
• VOGT MT, WOLFSON SK, KULLER LH: Lower extremity arterial disease and the aging process: a review. Epidemiol. (1992) 45:529–542.
   Google Scholar
• DORMANDY J: Peripheral vascular disease. Med. North Am. (1994) 34:353–360.
   Google Scholar
• GORDON T, KANNEL WB: Predisposition to atherosclerosis in the head, heart, and legs: the Framingham study. JAMA (1972) 221:661–666.
   PubMed Web of Science ®Google Scholar
• WILLIGENDAEL EM, TEIJINK JA, BARTELINK M-L et al.: Influence of smoking on incidence and prevalence of peripheral arterial disease. Vas. &mg. (2004) 40:1158–1165.
   PubMed Web of Science ®Google Scholar
• JONASON T, BERGSTROM R: Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med. Scand. (1987) 221:253–260.
   Google Scholar
• FARKOUH ME, RIHAL CS, GERSH BJ et al.: Influence of coronary heart disease on morbidity and mortality after lower extremity revascularization surgery: a population-based study in Olmsted County, Minnesota (1970–1987).1 Am. Coll Cardiol (1994) 24:190–1296.
   Google Scholar
• KANNEL WB, MCGEE DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study. J. Am. Ceriatr. Soc. (1985) 33:13–18.
   Google Scholar
• MURABITO JM, D'AGOSTINO RB, SILBERSHATZ H et al.: Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation (1997) 96:44-49. 2189 Expert Op/n. Pharmacother. (2005) 6(13)
   Google Scholar
• DIEHM N, SHANG A, SILVESTRO A et al.: Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur. j Vase. Endovasc. Surg. (2005) In Press.
   Google Scholar
• ADLER Al, STEVENS RJ, NEIL A et al: UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in Type 2 diabetes. Diabetes Care (2002) 25:894–899.
   PubMed Web of Science ®Google Scholar
• FOWKES FG, HOUSLEY E, RIEMERSMA RA et al: Smoking, lipids, glucose intolerance and blood pressure as risk factor for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am. 1. Epidemiol (1992) 135:331–340.
   Google Scholar
• EXPERT PANEL ON DETECTION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). "AMA (2001) 285:2486–2497.
   Google Scholar
• OLIJHOEK JK, VAN DER GRAAF Y, BANGA J-D et al: The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur. Heart J. (2004) 25:342–348.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, STAMPFER MJ, RIFAI N: Novel risk factors for systemic atherosclerosis. "AMA (2001) 285:2481–2485.
   PubMed Web of Science ®Google Scholar
• WEITZ JI, BYRNE J, CLAGETT GP et al.: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation (1996) 94:3026–3049.
   PubMed Web of Science ®Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension (2003) 42:1206–1252.
   PubMed Web of Science ®Google Scholar
• •Current guidelines for management of hypertension (US).
   Google Scholar
• MURABITO JM, EVANS JC, NIETO K, LARSON MG, LEVY D, WILSON PW: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am. Heart J. (2002) 143:961–965.
   PubMed Web of Science ®Google Scholar
• REGENSTEINER JG, HIATT WR: Current medical therapies for patients with peripheral arterial disease: a critical review. Am. J. Med. (2002) 112:49–57.
   PubMed Web of Science ®Google Scholar
• CRIQUI MH, LANGER RD, FRONEK A et al: Mortality over a period of ten years in patients with peripheral arterial disease. N Engl. J. Med. (1992) 326:381–386.
   PubMed Web of Science ®Google Scholar
• LEIBSON CL, RANSOM JE, OLSON W, ZIMMERMAN BR, O'FALLON WM, PALUMBO PJ: Peripheral arterial disease, diabetes, and mortality. Diabetes Care (2004) 27:2843–2849.
   PubMedGoogle Scholar
• KHAN S, CLEANTHIS M, SMOUT J, FLATHER M, STANSBY G: Life-style modification in peripheral arterial disease. Eur. J. Vas. Endovasc. Surg. (2005) 29:2–9.
   PubMedGoogle Scholar
• SOMMERFIELD T, HIATT WR: Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst. Rev (2004) 3:CD003833.
   Google Scholar
• BURNS P, GOUGH S, BRADBURY AW: Management of peripheral arterial disease in primary care. Br. Med. 1 (2003) 326:584–588.
   PubMed Web of Science ®Google Scholar
• QUICK CRG, COTTON LT: The measured effect of stopping smoking on intermittent claudication. BE J. Surg. (1982) 69:S24–S26.
   Google Scholar
• SMITH I, FRANKS PJ, GREENHALGH RM, POULTER NR, POWELL JT: The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial adisease and the onset of critical ischaemia. Eur. Vase. Endovasc. Surg. (1996) 11:402–408.
   PubMed Web of Science ®Google Scholar
• GIROLAMI B, BERNARDI E, PRINS MH et al.: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Int. Med. (1999) 159:337–345.
   PubMed Web of Science ®Google Scholar
• •Overview on noninvasive treatment for intermittent claudication.
   Google Scholar
• HOBBS SD, BRADBURY AW: Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach. Eur. Vase. Endovasc. Surg. (2003) 26:341–347.
   PubMedGoogle Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA et al: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl. J. Med. (1999) 340:685–691.
   PubMed Web of Science ®Google Scholar
• KARNATH B: Smoking cessation. Am. J. Med. (2002) 112:399–405.
   PubMed Web of Science ®Google Scholar
• HIGGINS M, KANNEL WB, GARRISON R, RINSKY J, STOKES J 3rd: Hazards of obesity - the Framingham experience. Acta Med. Scand. (1988) 723:23–26.
   PubMedGoogle Scholar
• PLANAS A, CLARA A, POU JM et al: Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int. 1. Obes. Relat. Meta. Disord. (2001) 25:1068–1070.
   PubMedGoogle Scholar
• VAN GAAL LF, RISSANEN AM, SCHEEN A, ZIEGLER O, ROSSNER S; FOR THE RIO-EUROPE STUDY GROUP: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascualr risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet (2005) 365:1389–1397.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALIST COLLABORATION: Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   Google Scholar
• CAVENDISH JJ, SAFANI M: Role of antiplatelet therapy in cardiovascular disease III: peripheral arterial disease. Curr. Med. Res. Opin. (2004) 20:1851–1855.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS'COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71–86.
   Google Scholar
• CLAGETT GP, SOBEL M, JACKSON MR, LIP GYH, TANGELDER M, VERHAEGHE RH: Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126:609S–626S.
   Google Scholar
• •Consensus on antithrombotic and thrombolytic therapy in patients with PAD.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Peripheral arterial disease in people with diabetes. Diabetes Care (2003) 26:3333–3342.
   PubMed Web of Science ®Google Scholar
• DIENER HC, BOGOUSSLAVSKY J, BRASS LM et al: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, 2190 Expert Op/n. Pharmacother. (2005) 6(1 3) placebo controlled trial. Lancet (2004) 364:331–337.
   Google Scholar
• DOGGRELL SA: Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding. Expert Opin. Pharmacother. (2005) 6:1253–1256.
   PubMed Web of Science ®Google Scholar
• Effect of intensive diabetes management onmacrovascular events and risk factors in the Diabetes Control and Complication trial. Am. J. Cardiol (1995) 75:894–903.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• PURNELL JQ, HOKANSON JE, MARCOVINA SM, STEFFES MW, CLEARY PA, BRUNZELL JD: Effects of exessive weight gain with intensive therapy of Type 1 diabetes on lipid levels and blood pressure: results from the DCCT. "AMA (1998) 280:140–146.
   PubMed Web of Science ®Google Scholar
• MEHLER PS, COLL JR, ESTACIO R, ESLER A, SCHRIER RW, HIATT WR: Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and Type 2 diabetes. Circulation (2003) 107:753–756.
   PubMed Web of Science ®Google Scholar
• ADLER Al, STRATTON IM, NEIL AW et al.: Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 36): prospective observational study. BE Med. J. (2000) 321:412–419.
   PubMed Web of Science ®Google Scholar
• RAY KK, CANNON CP: Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin. Pharmacother. (2005) 6:915–927.
   PubMed Web of Science ®Google Scholar
• STENDER S, SCHUSTER H, BARTER P, WATKINS C, KALLEND D; ON THE BEHALF OF THE MERCURY I STUDY GROUP: Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or witout the metablic syndrome in the MERCURY I trial. Diabetes, Obesity and Metabolism (2005) 7:430–438.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CNB et al: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation (2004) 110:227–239.
   PubMed Web of Science ®Google Scholar
• •Guidelines and recommendation for lipid-lowering therapy.
   Google Scholar
• LAROSA JC, GRUNDY SM, WATERS DD et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl. I. Med. (2005) 352:1425–1435.
   PubMed Web of Science ®Google Scholar
• COLLINS R, ARMITAGE J, PARISH Set al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7–22.
   Google Scholar
• PEDERSEN TR, KJEKSHUS J, PYORALA K et al: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol (1998) 81:333–335.
   PubMed Web of Science ®Google Scholar
• HIATT WR: Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. (2001) 344:1608–1621.
   PubMed Web of Science ®Google Scholar
• HIRSCH AT, CRIQUI MH, TREAT-JACOBSON D et al: Peripheral arterial disease detection, awareness, and treatment in primary care. "AMA (2001) 286:1317–1324.
   PubMed Web of Science ®Google Scholar
• HUANG JC, HOOGWERF BJ: Cholesterol guidelines update: more aggressive therapy for higher risk patients. Cleveland Clinic Journal of Medidne (2005) 72:253–263.
   PubMedGoogle Scholar
• PARRA D, BECKEY NP, RAVAL HS et al:Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol. Am. J. Card (2005) 95:1481–1483.
   PubMedGoogle Scholar
• GARG R, ELAM M, CROUSE J et al: Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am. Heart (2000) 140:792–803.
   PubMedGoogle Scholar
• GORDON T, CASTELLI WP, HJORTLAND MC et al: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. (1977) 62:707–714.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, PROBSTFIELD JL, GARRISON RJ et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circuation (1989) 79:8–15.
   Google Scholar
• ELAM MB, HUNNINGHAKE DB, DAVIS KB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randimized trial. "AMA (2000) 284:1263–1270.
   Google Scholar
• MEADE T, ZUHRIE R, COOK C, COOPER J: Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BE Med. I. (2002) 325:1139–1145.
   PubMed Web of Science ®Google Scholar
• MIKHAILIDIS DP, WIERZBICKI AS, DASKALOPOULOU SS et al.: The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr. Med. Eec. Opin. (2005) 21:959–970.
   PubMed Web of Science ®Google Scholar
• PEARSON T, DENKE M, MCBRIDE P et al: Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia. Programme and abstracts from the American College of Cardiology (2004); late Breaking Clinical Trials III. New Orleans, LA, USA.
   Google Scholar
• GUIDELINES COMMITTEE: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hyperten. (2003) 21:1011–1053.
   Google Scholar
• •Current guidelines for management of hypertension (Europe).
   Google Scholar
• RADACK K, DECK C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Int. Med. (1991) 151:1769–1776.
   PubMed Web of Science ®Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• HIRSCH AT, DUPREZ D: The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc. Med. (2003) 8:273–278.
   PubMedGoogle Scholar
• OSTERGREN J, SLEIGHT P, DAGENAIS G et al.: Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur. Heart J. (2004) 25:17–24.
   PubMed Web of Science ®Google Scholar
• JONASON T, BERGSTROM R: Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med. Scand. (1987) 221:253-260. 2191 Expert Opin. Pharmacother. (2005) 6(13)
   Google Scholar
• The TASC GROUP: Management of peripheral arterial disease. TransAtlantic Inter-Society Consensus (TASC). Vase. Surg. (2000) 31:1–304.
   PubMedGoogle Scholar
• •Comprehensive overview and consensus document on PAD.
   Google Scholar
• MOHLER ER, HIATT WR, CREAGER MA; FOR THE STUDY INVESTIGATORS: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation (2003) 108:1481–1486.
   PubMed Web of Science ®Google Scholar